---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-099700"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2026-09-14T20:05:41+00:00"
generated_at: "2026-09-14T20:07:34.710396+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# INmune Bio appoints Sanofi rare-disease GM and biopharma BD veteran to board

## Summary
- Board appointed R. Duane Clark II (Sanofi rare-disease GM) and James Sapirstein (CEO of Cocrystal) as independent directors.
- Each director gets option for 100,000 shares (36-month vest) plus $50,000 annual cash retainer.
- Board enlarged to seven; both join Nominating and Corporate Governance Committee.
- Appointments target rare-disease commercialization for Ebstrocel and strategic partnering across pipeline.

## SEC filing metadata
- accession: 0001213900-26-099700
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2026-09-14T20:05:41+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390026099700/0001213900-26-099700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390026099700/ea0305404-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-099700
- JSON: https://secwatch.observer/filing/0001213900-26-099700.json
- Plain text: https://secwatch.observer/filing/0001213900-26-099700.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.